| Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2014: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2012: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
|---|
| Outline of Final Research Achievements |
We found that CD28 stimuli induced short-lived but highly cytotoxic T cells whereas VLA-4/5 stimuli induced T cells with memory formation potential and high multifuctionality upon recall. We performed a phase I clinical trial with T cells with genetically engineered to express MAGE-A4-specific TCR for esophageal cancer patients. In this trial, we found that the long-term existence of the infused cells did not correlate with the clinical response when the patients did not receive lympho-depletive pre-treatment. Utilizing an original retroviral vector that inhibits the expression of endogenous TCR, we demonstrated a model of adoptive therapy with allogeneic T cells that induce less GvHD and increased tumor reactivity. We generated an antibody that reacted to the complex of HLA and a peptide from intracellular antigen and showed the usefulness of a chimeric antigen receptor that utilize this antibody.
|
